Synopsys (SNPS) CEO exercises options, sells 14,603 shares under 10b5-1 plan
Rhea-AI Filing Summary
Synopsys Inc. director and president/CEO Ghazi Sassine exercised equity awards and sold shares in a pre-planned transaction. On 2026-06-15, he exercised options and restricted stock units to acquire a total of 17,913 shares of common stock, including 14,603 shares from non-qualified stock options at an exercise price of $135.88 per share and 3,310 shares from restricted stock units that convert one-for-one into common stock.
On the same date, he sold 14,603 shares of common stock in open-market transactions at a weighted average price of $458.962 per share under a Rule 10b5-1 trading plan adopted on September 19, 2025, and 1,492 shares were withheld by the company to cover tax obligations related to RSU vesting. Following these transactions, he holds 75,020 shares of Synopsys common stock directly.
Positive
- None.
Negative
- None.
Insights
CEO’s option exercise, RSU vesting, and planned sale look like routine equity compensation activity.
Ghazi Sassine, president and CEO of Synopsys, exercised non-qualified stock options at an exercise price of $135.88 and vested restricted stock units that convert into common stock. This increased his shareholdings before subsequent dispositions.
He then sold 14,603 shares at a weighted average price of $458.962 per share and had 1,492 shares withheld to satisfy tax obligations tied to RSU vesting. The filing notes these trades were executed under a Rule 10b5-1 trading plan adopted on September 19, 2025, indicating they were pre-scheduled rather than opportunistic.
After all transactions, he directly holds 75,020 shares of common stock visible in this filing. With no remaining derivative positions reported here and the sales occurring under a pre-planned arrangement, the activity appears consistent with standard executive compensation and liquidity management rather than a directional call on the stock.
Insider Trade Summary 10b5-1
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Non-Qualified Stock Option (right to buy) | 14,603 | $0.00 | -- |
| Exercise | Restricted Stock Units | 3,310 | $0.00 | -- |
| Exercise | Common Stock | 14,603 | $135.88 | $1.98M |
| Sale | Common Stock | 14,603 | $458.962 | $6.70M |
| Exercise | Common Stock | 3,310 | $0.00 | -- |
| Tax Withholding | Common Stock | 1,492 | $454.38 | $678K |
Footnotes (1)
- Represents a weighted average sale price per share. These shares were sold in multiple transactions at prices ranging from $454.56 to $462.99. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares purchased at each separate price within the range. These shares were retained by the Company in order to meet the tax withholding obligations of the reporting person in connection with the vesting of an installment of the restricted stock unit award. The Compensation Committee approved the disposition of shares by the reporting person and the amount retained by the Company was not in excess of the amount of the tax liability. The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan that was adopted September 19, 2025. Each stock unit converts into one share of Synopsys common stock. One-sixth (1/6) of the units vest on the date shown followed by five equal semi-annual installments, subject to continued service through each vesting date.